The most frequently occurring lesions in the colon are the hyperplastic polyps (HP).
INTRODUCTION
In the general population the most frequently occurring lesion in the colon is the hyperplastic polyp (HP), with a prevalence in western populations of 10% to 35% (1) .
HP have long been considered as innocuous lesions with no malignant potential, whereas adenomatous polyps were recognized as neoplastic precursor lesions for colorectal adenocarcinomas.
However, large HP (size > 1cm) and the presence of multiple HP (number > 5) in hyperplastic polyposis syndrome have been clearly associated with colorectal adenomas or adenocarcinoma (2) (3) (4) (5) . In addition to these cases, more recent studies have suggested a link between HP and sporadic colorectal cancer. Huangl (6) found that patients with HP on initial colonoscopic examination have an increased incidence of colorectal adenomas on follow-up colonoscopy. Other groups have proposed the idea that HP may represent precursors of some sporadic colorectal cancers, particularly in the serrated neoplasia pathway (7) (8) (9) (10) . Despite these new data, the colonoscopy for patients with HP is not recommended, except after resection of one large hyperplastic polyp ( 1 cm) and/or multiple polyps (n 5) or if there is a family history of HP, neither in the guidelines from the French National Agency for Accreditation and Evaluation in Healthcare, nor by the American College of Gastroenterology (11, 12) .
Until now, there is no biomarker to identify the subset of HP that may have a malignant potential. However, data previously enounced strongly suggest that identifying a marker that could predict, with a good sensitivity and specificity, the occurrence of colonic neoplasm after resection of HP would be crucial for identifying the subset of patients at risk after HP who could benefit from a more suitable follow up strategy.
The hormone precursor progastrin (PG) is now recognized as a growth factor playing an important role in colon carcinogenesis. Transgenic mice overexpressing progastrin present an increased proliferative index in colonic mucosa. They also have an increased risk of developing preneoplastic lesions and adenocarcinomas in colonic epithelium when treated with a carcinogen, azoxymethane (13, 14) . The role of progastrin in proliferation, survival and migration of human colon cancer cells has also been clearly established (15) (16) (17) (18) (19) (20) . PG-growth promoting effects are mediated through the activation of several key signal transduction pathways (21, 22) . In addition, several works including ours showed that depletion of endogenous progastrin produced by colon cancer cells, leads to an inhibition of tumour growth (23, 24) . Moreover, high concentrations of PG are found in colon tumours and in blood of 80% of patients with colorectal cancer. Surgical resection of the tumour induces a dramatic decrease of PG levels in the serum, suggesting that the tumour itself is the source of PG (25) (26) (27) . PG is also expressed in adenomatous polyps (26, 28) , which represent neoplastic precursor lesions for colorectal adenocarcimas. In contrast, this hormone precursor is absent from the healthy intestinal epithelium.
All these data and our previous results suggested that progastrin may be a key factor of colon carcinogenesis and that its expression may predict the clinical outcome of early colonic lesions such as HP. In consequence, we investigated whether progastrin is expressed in hyperplastic polyps and determined whether its expression in HP is associated to the occurrence of colorectal cancer. We also assessed the performance of a predictive test based on progastrin staining of HP. 
MATERIALS AND METHODS

Study design
We conducted a single centre historical cohort study.
Sample size, patients and data collection
The required sample size for our study main endpoint, Neoplasm-free survival (NFS), was estimated for the logrank test using the method of Freedman and Schoenfeld, with STATA v11 software (STATACorp, Texas, USA). Thirty-eight patients were required. To demonstrate an association between progastrin staining and neoplasm occurrence, our sample size was calculated to detect a 4-fold increase in the hazard of the case group (minimum hazard ratio (HR) of 4) with 80% power. Based on our preliminary data, the probability of free-neoplasm surviving to the end of the study was set at 0.65 in the control group and prevalence of strong expression of progastrin at 50%. performed for surveillance purpose without particular colorectal pathology (see the exclusion criteria above). Approval of an institutional research ethics committee was obtained in accordance with the precepts of the Helsinki Declaration.
Immunohistochemistry
For immunohistochemistry on the formaldehyde-fixed, paraffin embedded tissues, heat Induced epitope retrieval was performed in Tris/EDTA buffer and primary antibodies were applied overnight. Detection was done using the DakoCytomation Envision+ System-HRP. Anti-progastrin antibody (1137) (29) kindly provided by Pr Shulkes was used for all the study (dilution used 1:1000). In additional experiments (when mentioned), anti-progastrin antibody H-90 (Santa Cruz) was used at the dilutions recommended by the provider.
Progastrin staining was measured by percentage of stained epithelial cells in the whole polyp. All specimens were examined in a double blinded fashion by two pathologists. Because the inter-rater agreement was excellent (ICC=0.9), percentages were reported as the average between the two readers.
Statistical analysis
Univariate analysis was conducted to compare clinical and immunohistochemistry findings between the different study groups using the Chi² test or Fisher exact test (when required) for categorical variables and Wilcoxon-Mann-Whitney for quantitative variables. We calculated intra-class correlation in order to determine inter-rater agreement for immunohistochemistry staining.
For neoplastic-free survival analysis, only patients with colonoscopic follow up data were included (39 patients). We performed Kaplan-Meier curves and log rank test to variables significantly associated with occurrence of a neoplastic event. To validate the classification tree, a bootstrap validation (30, 31) (with 100 bootstrap samples) was performed and the misclassification error rate estimated.
In our study, all tests were two-sided and statistical significance was set at a P value of 0.05. Analyses were performed using STATA v11 (32) and R (with "tree" and "ipred" packs).
Cancer Research. 
RESULTS
Patient and polyps characteristics
Clinical and pathologic features of patients and their polyps are shown in table 1. For the whole cohort, the median age of patients was 65 year old (y.o.) (sd : 14 y.o) and 43% of the patients were female. All polyps measured less than 1 cm with an average diameter of 3 mm, and the number of polyps at diagnosis was less than 5 for all the patients. Twenty % of HP were localized in the proximal colon and 80% in the distal colon, which is consistent with previous observations. In our sample, none HP displayed the major histological features described for sessile serrated adenomas figure 3A . Progastrin expression in HP was significantly different from the expression in normal colon (respectively, median: 45%, range: 0%-100%; versus 1%, range: 0%-10%, p=0.002). 100% of the tested adenomas or adenocarcinomas displayed an important expression of progastrin. As previously described (26, 28) , progastrin expression was higher in adenomas and adenocarcinomas than in normal colon (low grade dysplasia adenomas, p=0.001; high grade dysplasia adenomas, p=0.0007; adenocarcinomas, p=0.0005).
In normal colon, average percentage of progastrin staining was 2.6% (sd: 3.7%, range: 0-10). We considered, that progastrin staining was low when the percentage of staining was less than the 95 th percentile of the normal tissue (<10%). In the whole cohort, weak expression of progastrin (<10%) was found in 26% of the HP.
Expression of the prohormone was moderate (10%-50% of staining) in 34% of the HP and high (>50% of staining) in 40% of them ( Table 1) . The results were not significantly different in the patients group with colonoscopic follow up (weak expression 18%, moderate expression 36%, high expression 46%, p=0.26).
Patient neoplasm-free survival
Survival analysis was performed using data from patients who had at least one colonoscopy during their follow up. As mentioned above, clinical and immunohistological characteristics of these patients did not significantly differ from the other patients of the cohort. The median for the follow up period was 5 years (range [2] [3] [4] [5] [6] [7] [8] [9] [10] ). Only occurrence of metachronous adenomas at the same general area of the colon (proximal or distal colon) was considered as a recurrence event.
The overall median of neoplasm-free survival (S50%) was 8 years and survival at 5
years was 67% (95%CI: 49%-80%) ( Figure 3B ). Univariate analysis (Table 2) showed a significant association between progastrin overexpression and shortened neoplasm-free survival (p= 0.001). Patients with high expression of progastrin had a median neoplasm-free survival of 5 years, whereas during the 10 year following period, the median survival was not reached by patients with low expression of progastrin, since no recurrence occurred (Table 2, figure 3C ). The 5 year-neoplasmfree survival (5y.S) for the patients with weak progastrin expression was 100%, this value decreases to 84% for the patients with moderate expression and to 38% for the patients with high expression. In the same way, age was significantly associated with occurrence of adenoma (p<0.0001, for patients who were less than 64 year old:
5y.S=95% and S50%=10 years vs 5y.S=26% and S50%=5 years for older patients, Table 2 ).
To demonstrate that the association between progastrin staining and neoplasm-free survival was independent from the subject's age, HP localisation and HP size, we performed multivariate analysis (table 2) . After adjustment, progastrin expression was still highly significantly associated with adenoma occurrences (p<0.0001).
Taken together, these results show that progastrin staining in HP is an independent prognostic factor. As mentioned above, 41% of patients having an initial HP developed metachronous adenomas (Table 1) 
A predictive test for recurrence
To assess whether a predictive test using progastrin and age can predict occurrence of neoplasm after developing a first HP, we performed the receiver operating Figure 4A, 4B) . The predictive performance of progastrin and age were estimated by the area under the curve (AUC), which were, respectively, 0.81 (95%CI: 0.68-0.94) and 0.86 (95%CI: 0.74-0.98). Using the ROC curves, we also determined the best "diagnostic" threshold (i.e. with a 100% sensitivity to detect all the patients at risk to develop an adenoma and an optimal specificity) for each parameter in order to construct a classification tree. For progastrin staining, we chose the 40% -threshold (Sensitivity (Se)=100% and specificity (Spe)=57%) and for age the 54 y.o-threshold (Se=100% and Spe=48%). The classification tree, calculated with R software, shows that all patients with less than 40% of progastrin positive HP cells can be considered "at low risk". Among patients with more than 40% of PG staining in HP, only patients older than 54 y.o. can be considered as "at high risk" ( Figure 4C ). This composite test had a sensitivity of 100% (95%CI: 79%-100%), a specificity of 74% (51%-90%), a positive predictive value of 73% 95%CI: 50%-89%) and a negative predictive value of 100% (95%CI: 81%-100%). Misclassification error rate was 15% in our study sample. To estimate generalization error of classification, a bootstrap validation was performed. The out-of-bag misclassification error estimate was 25.6%. Among misclassification errors, no false negative was found and all neoplasm occurrences were detected. Therefore, we established a predictive test based on progastrin staining and patient's age that predicts occurrence of colonic neoplasm after developing a first HP. 
DISCUSSION
We show for the first time the expression of progastrin in HP. This supports the hypothesis that this hormonal precursor, known to be expressed in human colorectal adenomas and adenocarcinomas, could also play a pro-tumoral role at the very early stage of colonic carcinogenesis.
More importantly, we also showed that patients, whose HP displayed a strong expression of progastrin, were at higher risk to develop adenoma. These patients had a 5 year neoplasm free survival of 38% as compared to 100% for the patients with no/weak progastrin expression.
In our study, 41% of patients having HP developed metachronous adenomas. Only two patients showed recurrent hyperplastic polyps at follow up colonoscopy with a progastrin staining similar to the initial polyp. These results are in accordance with a previous study which reported a 2 times greater risk for subsequent colon neoplasia in patients having HP compared to HP free patients (6).
It is generally accepted that a subset of HP, named sessile serrated adenomas (SSA) by Torlakovic (4, 10), might be preneoplasic lesions. In our study, none HP displayed characteristics of SSA, such as architectural abnormalities and loss of MLH1 (33) . The metachronous adenomas that we observed in our cohort were all tubular or tubulo-villous adenomas and did not display histological feature of serrated adenoma nor carcinoma. However, the existence of an association between HP and classical neoplasms is not surprising since patients with hyperplastic polyposis develop both serrated and classical carcinomas. (supplementary data 3) . The Ras/Raf pathway is known to be activated in 50 to 80% of HP (36, 37) and some authors suggest its involvement in the development of hyperplastic lesions (6) . Since several studies have suggested a correlation between the Ras/Raf pathway activation and progastrin gene expression (34, 38) , this pathway might be responsible of the progastrin overexpression observed in the HP.
In our study, patients with HP presenting a high expression of progastrin were at higher risk to develop metachronous adenomas in the same localisation. This high expression of progastrin in HP might reflect an environmental background with greater risk for developing colorectal neoplasia. However, in our cohort three patients developed adenomas in another site than their original HP but progastrin was overexpressed (>50%) in only one of them while progastrin was overexpressed in all HP with occurrence at the same site. This result suggests that progastrin overexpression is not only a marker of pejorative background. Indeed, another hypothesis is the presence of molecular abnormality, such as progastrin expression, in these polyps but also in the adjacent colon. Interestingly, adjacent colonic epithelium of all HP with a high expression of progastrin also showed a strong expression of the hormonal precursor. In contrast, for all the hyperplastic polyps negative for progastrin, the surrounding unaffected mucosa was also negative. 
might be lower than histological security margin. Therefore, HP endoscopic excision might thus be not extensive enough to prevent a further neoplastic event. We demonstrated that progastrin staining could be an efficient tool to detect patients with higher risk of metachronous neoplasms. Based on our data, a test based on progastrin staining and age would display 100% of sensitivity and 74% of specificity.
In our study, there was no false negative patient (NVP=0). Thus patient with no progastrin overexpression, whatever their age, would have a low risk to develop metachronous neoplasm, whereas patients in our high progastrin expression group had a 73% risk of developing a neoplasm. Misclassification rate of our composite predictive test was only 15%. In this study, the sample size with colonoscopic follow up was restricted to 39 patients for several reasons. 
We performed a bootstrap cross-validation to estimate misclassification error. The out-of-bag misclassification rate estimate was 26%. Interestingly, none of the patients in our study cohort met the guidelines criteria for endoscopic surveillance, i.e. resection of one hyperplastic polyp 1 cm and/or multiple polyps (n 5) or a family history of hyperplastic polyps. Hence, a predictive test based on progastrin and age could be usefull to select a subset of patients who would benefit from colonoscopic surveillance. In our study, none of the patients has developed colorectal adenocarcinoma during their follow up. Nevertheless, because these patients have benefited an endoscopic surveillance although current guidelines do not recommend it, they could have been treated at adenoma stage before adenocarcinoma transformation.
We show for the first time that progastrin expression in HP is a strong independent predictive factor of risk for developing an adenoma and we establish here and propose a classification tree to select the population of patients who need a colonoscopic follow-up. In summary, we have demonstrated that progastrin staining in HP could be an efficient tool to detect patients with higher risk of metachronous neoplasms.
